Following a successful first patient treatment experience with TSHA-102, an adeno-associated virus vector-based gene therapy for Rett syndrome, Taysha Gene Therapies was recommended to continue with investigating the therapy in a second patient.
The director of headache medicine at The Mount Sinai Hospital talked about the often-overlooked realm of primary headaches beyond migraines as well as the importance of developing targeted treatments and increasing understanding of their pathophysiology. [WATCH TIME: 7 minutes]
The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.
What excites you? What awakens your sense of purpose? What gives your life meaning? Bradley McDaniels, PhD, CRC, explores the importance of meaning in one's life.
Episode 28 of the AUPN Leadership Minute features Donald S. Higgins, MD, of the VHA; and Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN, of University of Oxford. [WATCH TIME: 5 minutes]
The medical director of the North Texas Institute of Neurology and Headache offered an overview of the State of the Science Summit that was held on July 21, 2022, with a variety of expert clinicians in MS care. [WATCH TIME: 3 minutes]
Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.
The neuromuscular neurologist at the Cleveland Clinic discussed findings from an analysis presented at AANEM 2023 that investigated the safety and efficacy of subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 5 minutes]
The head of preclinical development at Imbrium Therapeutics provided an overview of positive safe and efficacy findings from the phase 2 study investigating sunobinop. [WATCH TIME: 4 minutes]
The founder and chief scientific officer of Neurolutions discussed complexities within the system to integrate new stroke rehab devices.
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the way to attack Alzheimer agitation and why drug solutions often fall short. [WATCH TIME: 3 minutes]
The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]
Episode 39 of the AUPN Leadership Minute features Donald S. Higgins Jr, MD, of Veterans Health Administration, Albany Medical College; and Alexandra Nelson, MD, PhD, of the University of California San Francisco. [WATCH TIME: 5 minutes]
The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. [WATCH TIME: 6 minutes]
The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about using a novel radiotracer to understand the movement of fluids and waste products in the brain. [WATCH TIME: 5 minutes]
Commenting on recent advances and persistent challenges for these patients, the associate professor of clinical occupational therapy at USC Keck Hospital spoke on the need to increase equity and access to care. [WATCH TIME: 6 minutes]
The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]
The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center detailed the difficulties with discussing neuroimmune disorders with newly diagnosed patients, including those who may not speak English. [WATCH TIME: 3 minutes]
The AASM board of directors' member and professor of medicine at UCLA discussed the benefits of CBT-I and its efficacy compared to pharmacological treatments.
The program director in the division of Neuroscience at the National Institute of Neurological Disorders and Stroke provided context on the importance of Rare Disease Day and strides made over the years. [WATCH TIME: 5 minutes]
The associate professor at Washington University School of Medicine provided commentary on the state of care for pediatric stroke, and the challenges with identifying the most likely etiology. [WATCH 3 minutes]
The postdoctoral researcher at King’s College London provided background on why gene therapies have not seen as much success in treating ALS, and the need for additional validation of genetic mutations. [WATCH TIME: 3 minutes]
The neurology resident at Magna Graecia University of Catanzaro also touched on how accurate early diagnoses can help hone clinical trial recruitment.
The professor of neurology at the University of Toronto provided insight on several prominent targets in the brain for deep brain stimulation, including emerging ones that may not gain as much attention. [WATCH TIME: 3 minutes]
The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.
The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about the need for clinicians to have more time with patients in clinical practice, particularly with those with chronic diseases. [WATCH TIME: 2 minutes]
The medical director of the Stroke Center at Weill Cornell Medicine talked about results from a recent study on the risk of stroke in patients on assisted reproductive technologies during delivery hospitalization. [WATCH TIME: 4 minutes]